

## Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel. : (91-22) 4324 4324  
Fax : (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
CIN: L24230GJ1993PLC019050



26 March, 2023

**National Stock Exchange of India Ltd.,**  
Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.  
**Scip Symbol: SUNPHARMA**

**BSE Limited,**  
Market Operations Dept.  
P. J. Towers,  
Dalal Street,  
Mumbai - 400 001.  
**Stock Code: 524715**

Dear Sirs/Madam,

### **Sub: Update on IT Security Incident**

Further to our intimation filed on 2<sup>nd</sup> March 2023, regarding an Information Technology (“IT”) security incident, we wish to provide an update.

The Company promptly took steps to contain and remediate the impact of the IT security incident, including employing containment and eradication protocols to mitigate the threat and additional measures to ensure the integrity of its systems infrastructure and data. These measures are underway as the Company utilizes global cyber security experts and enhanced security measures to address and mitigate the impact of the incident. A ransomware group has claimed responsibility for this incident.

The Company currently believes that the incident’s effect on its IT systems includes a breach of certain file systems and the theft of certain company data and personal data.

As part of the containment measures, we proactively isolated our network and initiated the recovery process. As a result of these measures, Company’s business operations have been impacted. Consequently, revenues are expected to be reduced in some of our businesses. The Company would incur expenses in connection with the incident and the remediation. The Company is currently unable to determine other potential adverse impacts of the incident, including but not limited to additional information security incidents, increased costs to maintain insurance coverage, the diversion of management and employee time or the possibility of litigation.

As and when required, appropriate further notification(s) will be made on the IT security incident.

This is for your information and dissemination.

Thanking you,

**For Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary & Compliance Officer**